• Deshan F Sebaratnam, Linda K Martin, Supriya S Venugopal, George Mangos, John Freiman, Paul de Souza, Annabelle Farnsworth, Karen Cheung, Richard A Scolyer, and Dédée F Murrell.
• Department of Dermatology, St George Hospital, Sydney, NSW, Australia; Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.
• Int. J. Dermatol. 2014 Nov 1; 53 (11): 1409-11.

Case ReportA 79-year-old Caucasian male presented with a 1-week history of diffuse progressive blue-gray discoloration of the skin subsequently found to due to diffuse melanosis cutis (DMC) in the setting of metastatic melanoma. Mutation testing demonstrated BRAF(V600E) mutation status, an unexpected finding given his age. He died two weeks after presentation.DiscussionAs our understanding of the molecular subtypes of melanoma increases, in the future it may be possible to predict which melanoma patients have a predilection to developing DMC. Mutation testing of DMC patients should be considered as BRAF inhibitors, and other novel targeted therapies may improve the bleak prognosis associated with this unusual presentation of metastatic melanoma.© 2014 The International Society of Dermatology.

18 keywords...

hide…